|
(Former) HHS Behavioral Health Coordinating Committee (BHCC) Subcommittee on Opioids and Controlled Substances
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, HIS, OS, OSG, SAMHSA
|
NIDA, OD/OSP
|
The National Institute of Drug Abuse (NIDA) Serves as Co-Chair with the Centers for Disease Control and Prevention (CDC) on this inter-agency subcommittee addressing prescription drug abuse.
|
|
12th Annual Conference on the Science of Dissemination and Implementation
|
Meeting/ Workshop
|
AHRQ
|
NHLBI, NCCIH, NCI, NIAAA, NIAID, NIDA, NIDDK, NIMH, NINR
|
A forum for discussing the science of dissemination and implementation, the 10th annual conference aimed to grow the research base by bridging the gap between evidence, practice, and policy in health and medicine.
|
|
2020 Surgeon General's Report on Oral Health
|
Resource Development
|
OASH
|
NIDCR
|
Commissioning of a Surgeon General's Report presenting prominent issues affecting oral health. The report will document progress in oral health in the twenty years since the 2000 Surgeon General's Report on Oral Health, identify existing knowledge gaps, and articulate a vision for the future.
|
|
3rd National Conference on Advancing Early Psychosis Care in the United States: Addressing Inequities - Race, Culture, and COVID
|
Meeting/ Workshop
|
SAMHSA
|
NIMH
|
With the rapid expansion of evidence-based early psychosis care in the U.S., largely the result of the successful NIMH-funded Recovery After an Initial Schizophrenia Episode (RAISE) initiative, additional clinician training on early psychosis is needed. The National Institute of Mental Health (NIMH), in collaboration with the Substance Abuse and Mental Health Services Administration (SAMHSA), sponsored a meeting entitled, "Advancing Early Psychosis Care in the United States: Addressing Inequities - Race, Culture, and COVID," on November 12-13, 2020. More than 3,000 clinicians and other professionals working in the early psychosis care field attended the virtual event. NIMH staff served on the planning committee and as presenters.
|
|
A nested case-control study of circulating per- and polyfluoroalkyl substances (PFAS) and renal cell carcinoma
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for a nested case-control study of renal cell carcinoma (RCC) in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
|
|
A nested case-control study of circulating per- and polyfluoroalkyl substances (PFAS) and uterine and ovarian cancers
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for nested case-control studies of endometrial (uterine) and ovarian cancers in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
|
|
A Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating on a cross-sectional study of 83 airline pilots and 50 university faculty to assess the relation of stable chromosome translocations with cosmic radiation exposure.
|
|
A Working Group to Consider the Question of Federal Public Health and Medical Resource Allocation
|
Committee, Work group, Advisory group, or Task Force
|
OS
|
CC
|
The National Institutes of Health (NIH) Clinical Center is participating in a working group to consider the question of federal public health and medical resource allocation. The group developed a framework for allocation of federal resources during scarcity after engaging with stakeholders in ethics, disaster preparedness, and emergency management.
|
|
A5349/TBTC S31 - Rifapentine - Containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-Label, Controlled Phase 3 Clinical Trial
|
Research Initiative
|
CDC
|
NIAID
|
The purpose of this research initiative is to provide scientific discovery to improve patient care and safety by reducing the duration of treatment for drug-susceptible pulmonary tuberculosis to 4 months by using new regimens, including high-dose rifapentine.
|
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT)
|
Research Initiative
|
FDA
|
NIDA
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) is part of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA). The mission of the (ACTTION) is to identify, prioritize, sponsor, coordinate, and promote innovative activities with a special interest in optimizing clinical trials that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of public health.
|